Document is current
Any future updates will be listed below
-
Authors
Park, Sanghyeon
Kim, Soyeon https://orcid.org/0000-0002-2798-2257
Kim, Beomsu
Kim, Dan Say
Kim, Jaeyoung https://orcid.org/0000-0001-6983-7907
Ahn, Yeeun https://orcid.org/0000-0002-8584-5322
Kim, Hyejin
Song, Minku
Shim, Injeong https://orcid.org/0000-0002-1001-0945
Jung, Sang-Hyuk
Cho, Chamlee https://orcid.org/0009-0002-3155-1932
Lim, Soohyun
Hong, Sanghoon
Jo, Hyeonbin
Fahed, Akl C.
Natarajan, Pradeep
Ellinor, Patrick T. https://orcid.org/0000-0002-2067-0533
Torkamani, Ali https://orcid.org/0000-0003-0232-8053
Park, Woong-Yang
Yu, Tae Yang https://orcid.org/0000-0003-0893-592X
Myung, Woojae https://orcid.org/0000-0001-9985-2032
Won, Hong-Hee https://orcid.org/0000-0001-5719-0552
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (NRF-2022R1A2C2009998, NRF-2021R1A2C4001779)
- License Information
-
More Information
Article History
Received: 19 October 2023
Accepted: 29 August 2024
First Online: 30 September 2024
Competing interests
: A.C.F. is cofounder of Goodpath. P.T.E. reports personal fees from Bayer AG, Novartis and MyoKardia. P.N. reports personal fees from Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Creative Education Concepts, CRISPR Therapeutics, Eli Lilly & Co., Foresite Labs, Genentech/Roche, GV, HeartFlow, Magnet Biomedicine, Merck and Novartis; scientific advisory board membership at Esperion Therapeutics, Preciseli and TenSixteen Bio; scientific cofounder status at TenSixteen Bio; equity in MyOme, Preciseli and TenSixteen Bio; and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work. W.-Y.P. was employed by the commercial company GENINUS. A.T. declares he is a cofounder and equity shareholder of GeneXwell Inc. A.T. is an advisor to InsideTracker. The other authors declare no competing interests.
